Optimizing Obesity Management With GLP‐1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review

GLP‐1 RAs are effective in treating obesity; however, they typically result in significant loss of skeletal muscle mass. Real‐world evidence to inform systematic guidelines and clinical implementation for preserving skeletal muscle mass and reducing cardiometabolic risk with lifestyle modifications on GLP‐1 RAs remains limited.